Effect of Valsartan on coronary restenosis after coronary intervention
LIU Yingzhi1 XIONG Zhenyu2 XIONG Longgen3
1.Department of Clinical Medicine, Guangzhou Medical University, Guangdong Province, Guangzhou 510000, China;
2.Department of Cardiology, the Second People′s Hospital of Guangdong Province, Guangdong Province, Guangzhou 510000, China;
3.Department of Cardiology, the Second Affiliated Hospital of Guangzhou Medical University, Guangdong Province, Guangzhou 510000, China
Abstract：Objective To investigate the effect of Valsartan on coronary restenosis after coronary intervention. Methods A total of 98 patients who underwent coronary intervention and stent placement at the Second Affiliated Hospital of Guangzhou Medical University from January 2016 to November 2017 were randomly divided into experimental group (n = 49) and control group (n = 49) according to the principle of randomly selected case numbers. The control group received routine treatment. The experimental group were treated with Valsartan Capsules on the basis of routine treatment. At the same time, 30 patients who underwent coronary angiography without stenting were selected as negative control group. The echocardiographic EF values, the occurrence of adverse cardiovascular events and coronary restenosis, and the contents of endothelin-1 (ET-1), high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), lipoprotein-related phospholipids and enzyme A2 (LP-PLA2) were analyzed in the three groups of patients. Results In the experimental group, there were 5 cases with coronary restenosis, with an incidence of 10.20%. In the control group, coronary restenosis occurred in 13 cases with an incidence of 26.53%, and the difference between the two groups was statistically significant (P < 0.05). The ET-1, hs-CRP, IL-6, LP-PLA2 and EF values of the three groups 4 weeks after surgery were compared with those before surgery, and the differences were statistically significant (P < 0.05). Four weeks after surgery, the differences of ET-1, hs-CRP, IL-6, LP-PLA2 and EF values in the experimental group, the control group and the negative control group were statistically significant (P < 0.05). Four weeks after surgery, experimental ET - 1, the hs-CRP, IL-6, LP-PLA2 were compared with control group, negative control group, and the differences were statistically significant (P < 0.05), while the control group compared with negative control group, there was no statistically significant difference (P > 0.05). Echocardiographic EF values of the experimental group, the control group and the negative control group were compared with those of the same group 4 weeks after surgery, and the differences were statistically significant (P < 0.05). EF values of the experimental group compared to control group, the difference was statistically significant (P < 0.05). The incidence of adverse cardiovascular events in the experimental group were less than that in the control group, and the difference was statistically significant (P < 0.05). Conclusion After coronary intervention, valsartan can effectively reduce the incidence of coronary restenosis, reduce the content of endothelin and inflammatory cytokines, and significantly improve the occurrence of adverse cardiovascular events and echocardiographic EF values.
2018, Vol. 15 
京公网安备 11010502046598号